Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy
Authors
Keywords
-
Journal
DIABETES CARE
Volume 45, Issue 4, Pages 898-908
Publisher
American Diabetes Association
Online
2022-03-03
DOI
10.2337/dc21-1288
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs
- (2021) Takahito Doi et al. EUROPEAN HEART JOURNAL
- Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
- (2021) Henry N Ginsberg et al. EUROPEAN HEART JOURNAL
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
- (2019) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
- (2019) Koutaro Yokote et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Efficacy and Safety of Pemafibrate in Patients with Type 2 Diabetes and Elevated Triglyceride levels: 52-Week Data From The PROVIDE Study
- (2019) Eiichi Araki et al. DIABETES OBESITY & METABOLISM
- The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
- (2019) Jean-Charles Fruchart et al. Cardiovascular Diabetology
- 23-LB: Lipoprotein Subfractions Are Associated with Diabetic Cardiovascular Disease and Death among 9,795 Patients in the FIELD Trial
- (2019) STEVEN R. JONES et al. DIABETES
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Clinical review on triglycerides
- (2019) Ulrich Laufs et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
- (2019) Yamashita et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate
- (2019) Yusuke Sasaki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia
- (2018) Shizuya Yamashita et al. Journal of Clinical Lipidology
- Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
- (2018) Shun Ishibashi et al. Journal of Clinical Lipidology
- Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol
- (2018) Gregory A. Nichols et al. DIABETES OBESITY & METABOLISM
- Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
- (2018) Aruna D. Pradhan et al. AMERICAN HEART JOURNAL
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials
- (2018) Amirhossein Sahebkar et al. BMJ Open
- Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
- (2016) Shun Ishibashi et al. ATHEROSCLEROSIS
- Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes
- (2015) Takahisa Hirose et al. Journal of Atherosclerosis and Thrombosis
- Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy
- (2014) Michael H. Davidson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Remnant cholesterol and ischemic heart disease
- (2014) Anette Varbo et al. CURRENT OPINION IN LIPIDOLOGY
- Triglycerides and cardiovascular disease
- (2014) Børge G Nordestgaard et al. LANCET
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
- (2012) J. C. Mychaleckyj et al. DIABETES CARE
- Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects
- (2011) Marja-Riitta Taskinen et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
- (2011) M. John Chapman et al. EUROPEAN HEART JOURNAL
- Fenofibrate, Homocysteine and Renal Function
- (2010) Christelle Foucher et al. Current Vascular Pharmacology
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate
- (2009) Marja-Riitta Taskinen et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started